Globus Medical (GMED)
Official siteHEALTHCARE • MEDICAL DEVICES • NYSE
Market Cap: $9.57B
Last updated: Nov 17, 2026 at 11:06 AM ET
Globus Medical (GMED) Earnings: Report Dates and Results
Globus Medical (GMED) is expected to report earnings on Feb 22, 2027. In the quarter ended Sep 30, 2026, Globus Medical reported EPS of $1.23, above the $1.20 estimate. It beat the EPS estimate in 7 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
GMED has an expected report date of Feb 22, 2027. Analysts' consensus for the quarter ending Dec 31, 2026 is 2.3% above the $1.28 reported for the quarter ended Dec 31, 2025.
GMED Earnings Call
The latest GMED earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 40 quarters below that had an estimate, GMED beat 28, missed 8 and matched 4. Revenue for the quarter ended Sep 30, 2026 was $763.72M, down 0.7% from $769.05M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | $1.23 | $1.20 | $1.13 - $1.26 | +2.50% | Beat | +4.2% | 13 | 9 up, 0 down | Nov 5, 2026 | $763.72M |
| Jun 30, 2026 | $1.34 | $1.12 | $1.05 - $1.14 | +19.64% | Beat | +55.8% | 15 | 12 up, 1 down | Aug 6, 2026 | $789.61M |
| Mar 31, 2026 | $1.12 | $0.92 | $0.80 - $1.06 | +21.74% | Beat | +64.7% | 13 | 6 up, 5 down | May 7, 2026 | $759.85M |
| Dec 31, 2025 | $1.28 | $1.15 | $1.06 - $1.26 | +10.96% | Beat | +52.4% | 13 | 7 up, 0 down | Feb 24, 2026 | $826.42M |
| Sep 30, 2025 | $1.18 | $0.78 | $0.61 - $0.82 | +51.28% | Beat | +42.2% | 14 | 3 up, 9 down | Nov 6, 2025 | $769.05M |
| Jun 30, 2025 | $0.86 | $0.76 | $0.72 - $0.82 | +13.16% | Beat | +14.7% | 13 | 3 up, 5 down | Aug 7, 2025 | $745.34M |
| Mar 31, 2025 | $0.68 | $0.75 | $0.68 - $0.81 | -9.33% | Miss | -5.6% | 15 | 0 up, 7 down | May 8, 2025 | $598.12M |
| Dec 31, 2024 | $0.84 | $0.75 | $0.65 - $0.87 | +12.21% | Beat | +40.0% | 14 | 2 up, 0 down | Feb 20, 2025 | $657.29M |
| Sep 30, 2024 | $0.83 | $0.65 | $0.59 - $0.68 | +27.69% | Beat | +45.6% | 15 | 0 up, 0 down | Nov 5, 2024 | $625.71M |
| Jun 30, 2024 | $0.75 | $0.68 | $0.64 - $0.73 | +10.29% | Beat | +19.0% | 15 | 0 up, 0 down | Aug 6, 2024 | $629.69M |
| Mar 31, 2024 | $0.72 | $0.57 | $0.49 - $0.62 | +26.32% | Beat | +35.8% | 15 | 1 up, 0 down | May 7, 2024 | $606.67M |
| Dec 31, 2023 | $0.60 | $0.61 | $0.57 - $0.97 | -1.64% | Miss | +1.7% | 15 | 1 up, 0 down | Feb 20, 2024 | $616.53M |
| Sep 30, 2023 | $0.57 | $0.57 | $0.51 - $0.58 | 0.00% | In line | +14.0% | 13 | 1 up, 1 down | Nov 7, 2023 | $383.64M |
| Jun 30, 2023 | $0.63 | $0.59 | $0.57 - $0.67 | +6.78% | Beat | +12.5% | 13 | 2 up, 0 down | Aug 3, 2023 | $291.62M |
| Mar 31, 2023 | $0.53 | $0.51 | $0.49 - $0.53 | +3.92% | Beat | +26.2% | 15 | 0 up, 0 down | May 4, 2023 | $276.69M |
| Dec 31, 2022 | $0.59 | $0.56 | $0.55 - $0.62 | +5.36% | Beat | +20.4% | 15 | 0 up, 1 down | Feb 21, 2023 | $274.50M |
| Sep 30, 2022 | $0.50 | $0.52 | $0.50 - $0.54 | -3.85% | Miss | 0.0% | 15 | 0 up, 1 down | Nov 8, 2022 | $254.15M |
| Jun 30, 2022 | $0.56 | $0.53 | $0.51 - $0.57 | +5.66% | Beat | 0.0% | 13 | 0 up, 0 down | Aug 4, 2022 | $263.65M |
| Mar 31, 2022 | $0.42 | $0.47 | $0.45 - $0.51 | -10.64% | Miss | -14.3% | 14 | 1 up, 1 down | May 10, 2022 | $230.55M |
| Dec 31, 2021 | $0.49 | $0.47 | $0.45 - $0.52 | +4.26% | Beat | -15.5% | 14 | N/A | Feb 17, 2022 | $250.02M |
| Sep 30, 2021 | $0.50 | $0.45 | $0.44 - $0.48 | +11.11% | Beat | +2.0% | 15 | 0 up, 0 down | Nov 4, 2021 | $229.72M |
| Jun 30, 2021 | $0.56 | $0.44 | $0.39 - $0.49 | +27.27% | Beat | +700.0% | 16 | N/A | Aug 4, 2021 | $251.02M |
| Mar 31, 2021 | $0.49 | $0.37 | $0.30 - $0.42 | +32.43% | Beat | +69.0% | 16 | N/A | May 4, 2021 | $227.34M |
| Dec 31, 2020 | $0.58 | $0.51 | $0.47 - $0.58 | +13.73% | Beat | +18.4% | 16 | N/A | Feb 17, 2021 | $233.44M |
| Sep 30, 2020 | $0.49 | $0.31 | $0.20 - $0.37 | +58.06% | Beat | +14.0% | 14 | N/A | Oct 28, 2020 | $216.10M |
| Jun 30, 2020 | $0.07 | -$0.11 | -$0.25 - $0.09 | +163.64% | Beat | -82.9% | 12 | N/A | Aug 5, 2020 | $148.92M |
| Mar 31, 2020 | $0.29 | $0.38 | $0.29 - $0.43 | -23.68% | Miss | -19.4% | 11 | N/A | May 7, 2020 | $190.58M |
| Dec 31, 2019 | $0.49 | $0.52 | $0.50 - $0.54 | -5.77% | Miss | +14.0% | 14 | N/A | Feb 20, 2020 | $211.67M |
| Sep 30, 2019 | $0.43 | $0.42 | $0.39 - $0.44 | +2.38% | Beat | +10.3% | 13 | N/A | Nov 6, 2019 | $196.22M |
| Jun 30, 2019 | $0.41 | $0.41 | $0.38 - $0.42 | 0.00% | In line | -6.8% | 13 | N/A | Aug 1, 2019 | $194.54M |
| Mar 31, 2019 | $0.36 | $0.41 | $0.40 - $0.44 | -12.20% | Miss | -12.2% | 13 | N/A | May 2, 2019 | $182.95M |
| Dec 31, 2018 | $0.43 | $0.39 | $0.38 - $0.43 | +10.26% | Beat | +13.2% | 13 | N/A | Feb 21, 2019 | $195.94M |
| Sep 30, 2018 | $0.39 | $0.32 | $0.31 - $0.34 | +21.88% | Beat | +30.0% | 11 | N/A | Nov 8, 2018 | $169.24M |
| Jun 30, 2018 | $0.44 | $0.35 | $0.30 - $0.36 | +25.71% | Beat | +37.5% | 11 | N/A | Aug 1, 2018 | $173.38M |
| Mar 31, 2018 | $0.41 | $0.36 | $0.35 - $0.37 | +13.89% | Beat | +36.7% | 10 | N/A | May 2, 2018 | $174.41M |
| Dec 31, 2017 | $0.38 | $0.35 | $0.33 - $0.36 | +8.57% | Beat | +22.6% | 12 | N/A | Feb 21, 2018 | $176.03M |
| Sep 30, 2017 | $0.30 | $0.30 | $0.28 - $0.31 | 0.00% | In line | +3.4% | 13 | N/A | Nov 8, 2017 | $151.74M |
| Jun 30, 2017 | $0.32 | $0.30 | $0.28 - $0.31 | +6.67% | Beat | +10.3% | 12 | N/A | Aug 2, 2017 | $152.39M |
| Mar 31, 2017 | $0.30 | $0.30 | N/A | 0.00% | In line | 0.0% | N/A | N/A | May 3, 2017 | $155.81M |
| Dec 31, 2016 | $0.31 | $0.33 | N/A | -6.06% | Miss | -3.1% | N/A | N/A | Feb 27, 2017 | $151.59M |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was $4.00, up 27.4% from the year before. It was $1.19 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | $4.00 | +27.4% |
| Dec 31, 2024 | $3.14 | +34.8% |
| Dec 31, 2023 | $2.33 | +12.6% |
| Dec 31, 2022 | $2.07 | N/A |
| Dec 31, 2021 | $2.04 | +42.7% |
| Dec 31, 2020 | $1.43 | -15.4% |
| Dec 31, 2019 | $1.69 | N/A |
| Dec 31, 2018 | $1.67 | +28.5% |
| Dec 31, 2017 | $1.30 | +9.2% |
| Dec 31, 2016 | $1.19 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 8,000 words across 14 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 8,044 | 14 | |
| 2026Q2 | Jun 30, 2026 | 7,131 | 13 | |
| 2026Q1 | Mar 31, 2026 | 8,666 | 15 | |
| 2025Q4 | Dec 31, 2025 | 9,572 | 16 | |
| 2025Q3 | Sep 30, 2025 | 8,373 | 13 | |
| 2025Q2 | Jun 30, 2025 | 10,029 | 14 | |
| 2025Q1 | Mar 31, 2025 | 6,066 | 13 | |
| 2024Q4 | Dec 31, 2024 | 10,077 | 15 |
2026Q3 Earnings Call
Opening remarks
Shagun Singh Senior Vice President of Strategy and Investor Relations Thank you for being with us today. Joining today's call from Globus Medical will be Keith Pfeil, President and Chief Executive Officer, and Kyle Kline, Chief Financial Officer. This review is being made available via webcast, accessible through the Investor Relations section of the Globus Medical website at www.globusmedical.com. As a reminder, our discussion may include forward-looking statements, and such statements are subject to risks and uncertainties that could cause actual and anticipated results to differ materially. Please refer to the cautionary language in the earnings release and in the company's filings with the Securities and Exchange Commission for additional information. Except as may be required by applicable law, we do not undertake to update any forward-looking statements. Additionally, we will be discussing certain non-GAAP financial measures on this conference call. We believe these non-GAAP financial measures provide additional information pertinent to our business performance. They should not, however, be considered replacements for, or be read other than together with, the most directly comparable GAAP financial measures. Additional information regarding these non-GAAP financial measures, as well as reconciliations for such non-GAAP measures, is included in the earnings release and is available on the Investor Relations section of the Globus Medical website. With that, I will now turn the call over to Keith Pfeil, our President and Chief Executive Officer.
Keith Pfeil President and Chief Executive Officer Thanks, Shagun, and good afternoon, everyone. Before I discuss the quarter, I'd like to formally welcome Shagun Singh to Globus as our new Senior Vice President of Strategy and Investor Relations. Shagun brings more than 20 years of health care investment research experience with deep expertise in medical technology and the investment landscape. She will lead our Investor Relations function as we expand engagement with our shareholders. As our business has grown in size and complexity, we separated Investor Relations from Corporate Development so that each has dedicated leadership. Brian Kearns, who has led both functions for the past 12 years, will continue as Senior Vice President of Corporate Development. I want to thank Brian for the work he's done, building relationships with many of you on this call. With that, let's turn to our third quarter results and the longer-term outlook. Our third quarter results totaled $763.7 million, declining 0.7% on an as-reported basis and declining 0.5% on a constant currency basis, reflecting the continued impacts of our rightsizing of Nevro, the timing of delayed new product launches within U.S. Spine, and lower contributions from competitive recruiting. Base business revenue, excluding Nevro, was $690 million, growing 3% as reported, while Nevro was $73.7 million, declining 25.7% compared to the prior-year quarter.
Frequently Asked Questions About GMED
When is Globus Medical's next earnings date?
Globus Medical's next earnings report is expected for Feb 22, 2027.
Did GMED beat earnings estimates last quarter?
Yes. Globus Medical reported EPS of $1.23 for the quarter ended Sep 30, 2026, above the $1.20 estimate, a 2.50% surprise.
What EPS do analysts expect from GMED next quarter?
The consensus EPS estimate for Globus Medical for the quarter ending Dec 31, 2026 is $1.31 from 17 analysts, with estimates from $1.21 to $1.39.
How often does GMED beat earnings estimates?
Globus Medical beat the EPS estimate in 7 of the last 8 quarters, with an average surprise of +15.27%.
GMED pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts